DMC vs. IRB: How Are They Different?

There's plenty of work that goes into facilitating clinical trials. From patient consent to oversight of data collection, clinical trials take a diverse set of skills and disciplines. In addition to understanding these areas, an important aspect of a clinical trial's organization is knowing how it is organized and how it impacts the services they offer. Teamwork is a crucial part of creating high-quality data in a clinical trial. This requires effective communication between different teams within the company. But do you know the differences between DMCs and IRBs? The following article provides an overview of these groups, their role in clinical trials, and how they work together to ensure quality data. There's plenty of work that goes into facilitating clinical trials. From patient consent to oversight of data collection, clinical trials take a diverse set of skills and disciplines. In addition to understanding these areas, an important aspect of a clinical trial's organization is knowing how it is organized and how it impacts the services they offer. Teamwork is a crucial part of creating high-quality data in a clinical trial. This requires effective communication between different teams within the company. But do you know the differences between DMCs and IRBs?  The following article provides an overview of these groups, their role in clinical trials, and how they work together to ensure quality data. What Are Data Monitoring Committees (DMCs)? A DMC is a group that has been officially approved by either the FDA or its local equivalent to monitoring data produced by a clinical trial. DMCs are cross-institute groups that are composed of patient representatives, statisticians or methodologies, clinical experts, and sponsors to ensure all data was collected correctly.  Typically comprised of 5-6 members, DMCs work independently from the study team by verifying the scientific validity of the data…

Continue Reading

Adaptive Research Appoints Mark Tsuchiyose, MD as Vice President, Clinical Affairs and Therapeutic Head, Gastroenterology, and Dhira Khosla, DO as Vice President, Strategic Clinical Partnerships, Positioning Company to Drive Continued Growth

SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- Adaptive Research Inc. (the “Company”), a healthcare ecosystem that enables community physicians to participate in clinical trials, thereby improving in-need patient access to innovative investigational agents or technologies under development while expanding access to a larger eligible patient pool for biotechnology and pharmaceutical Sponsors, today announced that Mark Tsuchiyose, MD and Dhira Khosla, DO have joined the executive team as Vice President, Clinical Affairs and Therapeutic Head, Gastroenterology, and Vice President, Strategic Clinical Partnerships, respectively.Dr. Tsuchiyose will lead the growth and expansion of the Company’s core businesses and identify other leaders in the field to enhance Adaptive Research mission. Dr. Tsuchiyose is a graduate from University of Southern California School of Medicine in 1983. He completed his Internal Medicine residency at Huntington Memorial Hospital in Pasadena, California and a gastroenterology fellowship at LAC/USC Medical Center. During his 25 years of practice, Dr. Tsuchiyose has been an Associate Clinical Professor at the University of California, San Francisco and a Section Chief in the division of Gastroenterology at Seton Medical Center and served as Chairman of Medicine.Dr. Khosla will lead the Company’s clinical strategic partner initiatives with the business development team. Dr. Khosla is an alumnus of the Philadelphia College of Osteopathic Medicine, completing her neurology residency at SUNY and fellowship in Electromyography and Neuromuscular at Stanford University. As a practicing physician, Dr. Khosla founded a private practice and served as a physician consultant and Principal Investigator for several organizations in the San Francisco Bay Area.“As we look towards 2021, I am pleased to announce the appointment of Dr. Tsuchiyose and Dr. Khosla to expand our current capabilities and offering to biotechnology and pharmaceutical Sponsors. Their respective leadership will be crucial to the successful growth of Adaptive Research,” stated Deepak Behera, MD, President and Chief…

Continue Reading

End of content

No more pages to load

Close Navigation